Haemonetics stock falls from recent highs amid weekly seller pressure and overbought signals

Traders Union
All News
Companies
Haemonetics drops 1.26% today

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Sholanke Dele

Yesterday

Haemonetics stock falls from recent highs amid weekly seller pressure and overbought signals — Haemonetics drops 1.26% today

Haemonetics will present at the Goldman Sachs 47th Annual Global Healthcare Conference, according to the company.

A link to more information was shared in the announcement. Details are being clarified.

Highlights

HAE remains in a broad sideways range, with price action supported above $64.00 and resistance near $68.00.
Multiple momentum and volatility signals indicate the stock is overbought, with weak trend strength and increased risk of a near-term pullback.
Probability of an upside breakout is low; a move below $64.00 could trigger renewed downside toward key support at $62.53.

Bullish technical structure as price holds above key moving averages

HAE is trading at $66.37, above its MA-20 ($59.35), MA-50 ($58.96), and MA-200 ($62.53), which confirms a constructive short-, medium-, and long-term bullish bias. The Ichimoku Kijun level on D1 stands at $59.77, acting as immediate support below the current price. Near-term support is clustered at MA-200 ($62.53), with key support at the MA-100 ($62.25). Resistance sits first at the MA-5 cluster ($67.21), and key resistance is formed by the MA-10 ($63.72) and Ichimoku Kijun ($59.77) remaining below, but the next notable resistance is the MA-5/MA-10 zone above.

Mixed momentum and overbought signals as weekly pullback continues

Momentum indicators paint a mixed picture: MACD on D1 holds a buy signal while ADX remains neutral, reflecting low trend strength. RSI on D1 is elevated at 68.32, showing mild overbought conditions, and Stoch RSI and CCI confirm the market is overbought. BBP highlights dominance of buyers, but HMA D1 points to a near-term sell bias, indicating conflicting signals. Awesome Oscillator aligns modestly with the bullish theme. HAE has fallen $1.44 or 2.12% this week, trading down from $67.81 a week ago. The price is currently in the middle of the weekly range, with weekly volatility standing at 5.46%. The week’s tone reflects a steady decline from recent highs within a broad sideways range. In today's session, HAE lost 1.26%—a notable move indicating short-term seller pressure.

Downside risk favored as limited bullish signals constrain breakout odds

Looking ahead, the expected price range for the coming week is $64.00 to $68.00, situating action well above the 52-week low of $47.32 and below the 52-week high of $87.32. The probability of an upward move is very low (less than 20%) given only one out of four key W1 indicators (RSI) shows a bullish signal, making a downward move more likely. The baseline scenario is for HAE to remain range-bound between $64.00 and $68.00 as buyers and sellers compete for control. In a bullish scenario, clearing the $68.00 resistance may trigger a retest of higher levels toward MA-100 W1 ($68.88), but significant weekly resistance and overbought oscillators limit break-out odds. In a bearish outcome, slipping below $64.00 risks a retest of broader support zones near the MA-200 D1 ($62.53) but would remain well above the major annual lows, illustrating that the short-term structure is still broadly constructive unless support levels fail.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Haemonetics launched its latest Hospital Solutions aimed at enhancing procedural effectiveness and patient outcomes. Investors should monitor whether the company’s ongoing innovation translates into sustained market performance, with particular attention to any shifts in clinical adoption trends.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.